Canada markets open in 6 hours 32 minutes

Roche Holding AG (RHHBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
417.50+2.05 (+0.49%)
At close: 03:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close415.45
Open416.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range416.50 - 417.50
52 Week Range340.10 - 473.65
Volume37
Avg. Volume93
Market Cap274.107B
Beta (5Y Monthly)0.29
PE Ratio (TTM)22.69
EPS (TTM)18.40
Earnings DateN/A
Forward Dividend & Yield9.97 (2.39%)
Ex-Dividend DateMar 17, 2022
1y Target EstN/A
  • Zacks

    Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust

    Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.

  • Zacks

    Blueprint Medicines' (BPMC) Q2 Earnings & Revenues Miss Mark

    Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.

  • Business Wire

    Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results

    SOUTH SAN FRANCISCO, Calif., August 02, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq® (atezolizumab) met its co-primary endpoints. The study showed non-inferior levels of Tecentriq in the blood (pharmacokinetics), when injected subcutaneously, compared with intravenous (IV) infusion, in cancer immunotherapy-naïve patients with locally advanced or metastatic non-smal